C71T
CANCELLED SECTION 71
02/06/2026
Back to search
Official data from USPTO
NMD PHARMA NEUROMUSCULAR DISORDERS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
03/03/2026
Trademark type
Combined
Nice classes
5, 42
Filing date
05/18/2018
Registration date
07/23/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/06/2026
Last transaction
03/03/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
DK
Examiner
KIDWELL WALKER, JACLYN NOEMI
Law office
L20
Current location
TMEG LAW OFFICE 102
Mark description
The mark consists of the letters "NMD" in dark grey with a green diamond over the letter "M" followed by the word "PHARMA" in light grey over the wording "NEUROMUSCULAR DISORDERS" in light grey.
Holders and representatives
Holders
NMD Pharma A/S
Representatives
Joel D. Leviton STINSON LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Chemical-pharmaceutical preparations for the treatment of rare and genetic diseases; chemical-pharmaceutical preparations for the treatment of neurodegenerative diseases; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders; chemical-pharmaceutical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by compromised skeletal muscle excitability; diagnostic preparations for medical purposes; reagents for medical purposes and for research ; preparations for analysis for medical and research purposes; pharmaceutical and medical preparations for the treatment of rare and genetic diseases; pharmaceutical and medical preparations for the treatment of neurodegenerative diseases; pharmaceutical and medical preparations for the treatment of neuromuscular disorders; pharmaceutical and medical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; pharmaceutical and medical preparations for acute hospital carechemical-pharmaceutical preparations for the reversal of neuromuscular blockadechemical-pharmaceutical preparations for the treatment of intensive care unit acquired muscle weaknesschemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by infections
Class 42
Scientific and technological services and researchresearch in the field of medicine and the development of pharmaceutical preparations; industrial analysis and research services in the field of development of pharmaceutical preparationsin the field of identification of drug candidates; drug discovery services; basic research and clinical researchhereunder in the field of medicine and vaccine development; development of medical treatments related to rare and genetic diseases; development of medical treatments related to neurodegenerative diseases; development of medical treatments related to neuromuscular disorders; development of medical treatments that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; development of medical treatments for acute hospital care
Publications
History of USPTO decisions and trademark events.
38 publications found
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/23/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
09/09/2023
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
09/03/2020
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
07/26/2020
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/06/2019
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
11/21/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/21/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/14/2019
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
11/14/2019
FIMP
FINAL DISPOSITION PROCESSED
11/14/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/23/2019
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
08/23/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
07/23/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/07/2019
PUBO
PUBLISHED FOR OPPOSITION
05/07/2019
GPNX
NOTIFICATION PROCESSED BY IB
05/03/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/30/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/17/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/17/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/17/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/18/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
03/18/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/18/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
03/18/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/18/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/05/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/04/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/04/2019
RFNT
REFUSAL PROCESSED BY IB
10/13/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/22/2018
RFRR
REFUSAL PROCESSED BY MPU
09/22/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/18/2018
CNRT
NON-FINAL ACTION WRITTEN
09/17/2018
DOCK
ASSIGNED TO EXAMINER
09/10/2018
MAFR
APPLICATION FILING RECEIPT MAILED
08/21/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/15/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/09/2018
Continuous trademark protection
Get notified about every new filing that threatens NMD PHARMA NEUROMUSCULAR DISORDERS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.